SYSTEMATIC REVIEW article

Front. Oncol.

Sec. Cancer Molecular Targets and Therapeutics

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1584622

Prognostic and Clinicopathological Value of DBC1 Expression in Human Cancers: A Systematic Review and Meta-Analysis

Provisionally accepted
Haojia WangHaojia Wang1,2Xinhong ChengXinhong Cheng1,2Xianzhuo ZhangXianzhuo Zhang3Yong WangYong Wang4Shuo GaoShuo Gao1,2Fanghui DingFanghui Ding1,2Xiaojing SongXiaojing Song1,2Dandan LiDandan Li1,2Haixu NiHaixu Ni1,2Yang LuoYang Luo1,2*Xun LiXun Li1,2*
  • 1Lanzhou University, Lanzhou, China
  • 2First Hospital of Lanzhou University, Lanzhou, Gansu Province, China
  • 3Faculty of Health Sciences, University of Macau, Macau, Shanghai Municipality, China
  • 4The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Background: DBC1 is a large nuclear protein that is thought to influence the development of several human cancers. However, further research has revealed that the relationship between DBC1 and the prognosis and pathological characteristics of cancer patients is controversial. The aim of this paper is to explore the significance of DBC1 in cancer through the method of meta-analysis. Methods: A systematic search of the PubMed, Web of Science, Embase, CNKI, and Wanfang databases was conducted, resulting in the identification of 25 studies encompassing 4014 patients. The Hazard Ratio (HR) and ratio ratios (RR) were combined using STATA 14.0 software, and 95% confidence intervals (CI) were obtained to assess the association of DBC1 with prognostic and pathologic characteristics of cancer patients.Results: Meta-analysis of the combined results demonstrated that patients with cancer who exhibited DBC1 overexpression exhibited shorter overall survival (OS) (n = 17, HR = 1.948,], P = 0.002, I 2 = 88.6) and recurrence-free survival (RFS) (n = 11, HR = 2.182, 95%CI: [1.430-3.330], P = 0.000, I 2 = 87.8) rates. In terms of pathological features, elevated DBC1 expression was indicative of poor TNM stage (n = 23,

Keywords: DBC1, Carcinoma, Meta-analysis, prognosis, Clinicopathological characteristics

Received: 27 Feb 2025; Accepted: 06 Jun 2025.

Copyright: © 2025 Wang, Cheng, Zhang, Wang, Gao, Ding, Song, Li, Ni, Luo and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Yang Luo, Lanzhou University, Lanzhou, China
Xun Li, Lanzhou University, Lanzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material